Search clinical trials for: ABL001 Nilotinib

Total 3232 results

Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
BioNTech RNA Pharmaceuticals GmbH

Completed

IVAC MUTANOME Phase I Clinical Trial

Melanoma

Austria, Germany
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Novartis Pharmaceuticals

Active, not recruiting

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)

Chronic Myeloid Leukemia

Italy
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, India, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa and more
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
Novartis Pharmaceuticals

Active, not recruiting

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
ABL Bio, Inc.

Recruiting

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

Healthy

United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Alector Inc.
GlaxoSmithKline

Enrolling by invitation

Continuation Study for Latozinemab

Neurodegenerative Diseases

Canada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Leukemia, Chronic Myelogenous

China
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Mild to Moderate COVID-19

China
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Frontier Biotechnologies Inc.

Completed

A Bridging Study of FB2001 in Healthy Subjects

COVID-19

China
AB Science

Completed

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

COVID-19

China
Frontier Biotechnologies Inc.

Completed

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Covid19

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
ObsEva SA

Completed

OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI (IMPLANT)

Infertility

Poland, United Kingdom, Spain, Belgium, Denmark, Czechia
Zhongnan Hospital
Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Abion Inc
Novotech (Australia) Pty Limited

Recruiting

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Advanced Solid Tumors

Australia, Korea, Republic of
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

Postmenopausal Osteoporosis

China
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Ruijin Hospital
Frontier Biotechnologies Inc.; Shanghai Center for Disease Control and Prevention

Not yet recruiting

Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts

Close Contact Transmission
Abcuro, Inc.
Syneos Health

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Inclusion Body Myositis

United States, Australia, Belgium, France, Canada, Germany, United Kingdom
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Norgine

Completed

Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights

Incontinence

United Kingdom
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Frontier Biotechnologies Inc.

Completed

A Study of FB2001 for Inhalation in Healthy Chinese Adults

COVID-19 Pandemic

China
Sound Biopharmaceuticals Ltd.

Recruiting

Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001

Solid Tumor

China
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Abcuro, Inc.

Recruiting

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

T-cell Large Granular Lymphocytic Leukemia

United States
Abcuro, Inc.

Active, not recruiting

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Inclusion Body Myositis

Australia

Search clinical trials for: ABL001 Nilotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations